WNT2B and non-small cell lung carcinoma: Specifically, WNT2B protein levels in NSCLC patient tissues have demonstrated a significant increase compared with normal tissues and correlating with unfavorable patient outcomes (Huang et al., 2015), furthermore chronic treatment with sotorasib has been associated with WNT expression and activation of the WNT/β-catenin signaling pathway (Mohanty et al., 2023).